1. European Medicines Agency: https://www.ema.europa.eu/en/medicines//human/EPAR/baqsimi#product-information-section. Accessed June, 29, 2020.
2. Guzman CB, Dulude H, Piché C, et al. Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obes Metab 2018; 20(3): 646–653.
3. Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes:a randomized crossover noninferiority study. Diabetes Care 2016; 39: 264–270.
4. Seaquist ER, Dulude H, Zhang XM, et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab 2018; 20: 1316–1320.
5. Suico J, Hövelmann U, Zhang S, et al. Nasal glucagon: a viable alternative to treat insulin-induced hypoglycaemia in adults with type 1 diabetes. Diabetologia 2018; 61(Suppl 1): 77–78.
6. Yale JF, Dulude H, Egeth M, et al. Faster use and fewer failures with needle-free nasal gucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther 2017; 19(7): 423–432. doi: http://dx.doi.org/10.1089/dia.2016.0460